The Significance of Proteomic Biomarkers in Male Breast Cancer

被引:0
作者
Zografos, Eleni [1 ]
Gazouli, Maria [1 ]
Tsangaris, Georgios [2 ]
Marinos, Evangelos [1 ]
机构
[1] Univ Athens, Sch Med, Dept Basic Med Sci, Biol Lab, GR-11527 Athens, Greece
[2] Acad Athens, Biomed Res Fdn, Prote Res Unit, Ctr Basic Res 2, Athens, Greece
关键词
Male breast cancer; proteomics; genetics; biomarkers; review; CLINICAL PROTEOMICS; ESTROGEN-RECEPTOR; RISK-FACTORS; EXPRESSION; GENE; MEN; CARCINOMA; P53; DISCOVERY; SUBTYPES;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Breast cancer in men (MBC) is an uncommon malignancy and accounts for only 1% of all diagnosed breast cancers. By using genomic and transcriptomic approaches, researchers have been able to expand our insight into the genetic basis of breast cancer, by providing new biomarkers. We currently know that gene analysis by itself does not show the complete picture. Along with the genomic approach, proteomics are crucial for the improvement of breast cancer diagnosis, sub-classification, for predicting response to different treatment modalities and for predicting prognosis. There are great challenges in identifying discriminatory proteins and the use of specific techniques along with additional analytical tools is required. A number of techniques allow testing for proteins produced during specific diseases. In this review, an effort is made to summarize the studies and results linked to the implementation of proteomics in the field of MBC detection and diagnosis.
引用
收藏
页码:183 / 190
页数:8
相关论文
共 88 条
[1]   Perspective: A program to improve protein biomarker discovery for cancer [J].
Aebersold, R ;
Anderson, L ;
Caprioli, R ;
Druker, B ;
Hartwell, L ;
Smith, R .
JOURNAL OF PROTEOME RESEARCH, 2005, 4 (04) :1104-1109
[2]   Male and female breast cancer -: Differences in DNA ploidy, p21 and p53 expression reinforce the possibility of distinct pathways of oncogenesis [J].
Andre, Saudade ;
Pinto, Antonio E. ;
Laranjeira, Catia ;
Quaresma, Manuela ;
Soares, Jorge .
PATHOBIOLOGY, 2007, 74 (06) :323-327
[3]  
ANELLI A, 1995, CANCER, V75, P2233, DOI 10.1002/1097-0142(19950501)75:9<2233::AID-CNCR2820750907>3.0.CO
[4]  
2-S
[5]  
[Anonymous], 2015, CANC FACTS FIG 2015
[6]  
[Anonymous], J CARCINOG MUTAGEN S
[7]  
Aschie M, 2013, ROM J MORPHOL EMBRYO, V54, P749
[8]   Status of HER-2 in male and female breast carcinoma [J].
Bloom, KJ ;
Govil, H ;
Gattuso, P ;
Reddy, V ;
Francescatti, D .
AMERICAN JOURNAL OF SURGERY, 2001, 182 (04) :389-392
[9]   Male breast cancer in the hereditary nonpolyposis colorectal cancer syndrome [J].
Boyd, J ;
Rhei, E ;
Federici, MG ;
Borgen, PI ;
Watson, P ;
Franklin, B ;
Karr, B ;
Lynch, J ;
Lemon, SJ ;
Lynch, HT .
BREAST CANCER RESEARCH AND TREATMENT, 1999, 53 (01) :87-91
[10]   Prediagnostic Sex Steroid Hormones in Relation to Male Breast Cancer Risk [J].
Brinton, Louise A. ;
Key, Tim J. ;
Kolonel, Laurence N. ;
Michels, Karin B. ;
Sesso, Howard D. ;
Ursin, Giske ;
Van Den Eeden, Stephen K. ;
Wood, Shannon N. ;
Falk, Roni T. ;
Parisi, Dominick ;
Guillemette, Chantal ;
Caron, Patrick ;
Turcotte, Veronique ;
Habel, Laurel A. ;
Isaacs, Claudine J. ;
Riboli, Elio ;
Weiderpass, Elisabete ;
Cook, Michael B. .
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (18) :2041-2050